首页> 外文期刊>Expert opinion on therapeutic targets >Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target.
【24h】

Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target.

机译:Raf激酶抑制蛋白(RKIP):一种生理调节剂和未来的治疗目标。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Raf kinase inhibitory protein (RKIP) belongs to the phosphatidylethanolamine binding protein (PEBP) family that is expressed in both prokaryotic and euakaryotic organisms. OBJECTIVE: In this review, we discuss the role of RKIP as a modulator of signal transduction, the relationship of RKIP to other members of the PEBP family, and the role of RKIP in human health and disease. RESULTS/CONCLUSION: In mammals, RKIP regulates activation of MAPK, NF-kappaB and G protein coupled receptors (GPCRs). As a modulator of key signaling pathways, RKIP affects various cellular processes including cell differentiation, the cell cycle, apoptosis and cell migration. Emerging evidence suggests that RKIP is implicated in several human diseases or disorders, among them metastatic tumorigenesis and Alzheimer's disease.
机译:背景:Raf激酶抑制蛋白(RKIP)属于在原核和真核生物中均表达的磷脂酰乙醇胺结合蛋白(PEBP)家族。目的:在本文中,我们讨论了RKIP作为信号转导调节剂的作用,RKIP与PEBP家族其他成员的关系以及RKIP在人类健康和疾病中的作用。结果/结论:在哺乳动物中,RKIP调节MAPK,NF-κB和G蛋白偶联受体(GPCR)的激活。作为关键信号通路的调节剂,RKIP影响各种细胞过程,包括细胞分化,细胞周期,凋亡和细胞迁移。越来越多的证据表明,RKIP与几种人类疾病或病症有关,其中包括转移性肿瘤发生和阿尔茨海默氏病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号